{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answer.dateOfAnswer=2019-05-22&uin=255651", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?answer.dateOfAnswer=2019-05-22&uin=255651", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answer.dateOfAnswer=2019-05-22&uin=255651&_metadata=all", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&answer.dateOfAnswer=2019-05-22&uin=255651", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answer.dateOfAnswer=2019-05-22&uin=255651", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answer.dateOfAnswer=2019-05-22&uin=255651", "items" : [{"_about" : "http://data.parliament.uk/resources/1127283", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1127283/answer", "answerText" : {"_value" : "<p>The 2019 Voluntary Scheme for Branded Medicines Pricing and Access, and the statutory scheme for branded medicines pricing, work together to control the cost of branded medicines to the National Health Service and ensure it stays within affordable limits.<\/p><p> <\/p><p>The 2019 Voluntary Scheme began on 1 January 2019 and will run for five years until the end of 2023. The Voluntary Scheme aims to provide stability and predictability for all parties in terms of the United Kingdom\u2019s branded medicines expenditure and the medicines pricing and access environment for the period 2019 to 2023. It also aims to achieve a balance between patient access, affordability and supporting the development of innovative new medicines, including support for small companies.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"}
        }
        , "answeringMemberConstituency" : {"_value" : "South Ribble"}
        , "answeringMemberPrinted" : {"_value" : "Seema Kennedy"}
        , "dateOfAnswer" : {"_value" : "2019-05-22", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2019-05-22T14:30:06.757Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2019-05-17", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "NHS: Drugs"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps his Department is taking to encourage fairer pricing by pharmaceutical companies for drugs supplied to the NHS.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/308", "label" : {"_value" : "Biography information for Mr Jim Cunningham"}
      }
      , "tablingMemberConstituency" : {"_value" : "Coventry South"}
      , "tablingMemberPrinted" : [{"_value" : "Mr Jim Cunningham"}
      ], "uin" : "255651"}
    ], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 1, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}